Sandrine Mace
Sanofi R&D
Vitry-sur-seine, France
Vitry-sur-seine, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.
Journal: Future oncology (London, England)
Published: June 27, 2026
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer.
Journal: JCI insight
Published: June 27, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 18, 2025
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study.
Journal: HemaSphere
Published: February 17, 2025
Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials.
Journal: Annals of hematology
Published: December 24, 2024
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Journal: The New England journal of medicine
Published: June 04, 2024
A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Journal: Haematologica
Published: May 19, 2024
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Journal: European journal of haematology
Published: March 29, 2024
Last Updated: 09/26/2026